Form 4: Veracyte Director David Shafer Awarded 9,321 Restricted Stock Units

Veracyte, Inc. Director David Brent Shafer was awarded 9,321 restricted stock units, increasing his beneficial ownership to 25,828 shares.

Summary

• David Brent Shafer, a Director of Veracyte, Inc. (VCYT), was awarded 9,321 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on June 18, 2025.
• The RSUs were awarded at a price of $0 per share.
• Following this transaction, Mr. Shafer's beneficial ownership of Veracyte Common Stock increased to 25,828 shares.
• The RSUs vest in full on the first anniversary of the grant date (June 18, 2026) or immediately prior to the Company's next annual meeting of stockholders, if earlier.
• The RSUs also vest in full in the event of a change in control of Veracyte, Inc.

Sentiment

Score: 7

Explanation: The award of restricted stock units to a director is a positive event for the individual and a standard practice for the company to incentivize long-term commitment, reflecting routine corporate governance and compensation.

Positives

• The award of 9,321 restricted stock units to Director David Brent Shafer aligns his interests with those of the company's shareholders.
• The vesting schedule incentivizes long-term commitment and performance from the director.

Future Outlook

The vesting schedule for the restricted stock units indicates a future commitment period for Director David Brent Shafer, with full vesting expected by June 18, 2026, or earlier under specific conditions such as the company's next annual meeting of stockholders or a change in control.

Industry Context

The award of restricted stock units to a director is a common practice in the biotechnology and diagnostics industry, used to align executive and director interests with long-term shareholder value and incentivize retention.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard compensation mechanism widely adopted across publicly traded companies, including those in the healthcare and diagnostics sectors, to foster long-term alignment between leadership and shareholder interests.

Corporate Governance

Related Party Transactions

• Award of 9,321 restricted stock units to David Brent Shafer, a Director of Veracyte, Inc., as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the director's interests with long-term company performance and shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Vesting of the 9,321 restricted stock units on the first anniversary of the grant date (June 18, 2026) or prior to the next annual meeting of stockholders, if earlier.
• Potential accelerated vesting of the restricted stock units upon a change in control of Veracyte, Inc.

Key Dates

Keywords

Veracyte, VCYT, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Stock Award